AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
The treatment showed effectiveness in achieving local control of acute myeloid leukemia (AML) that developed in the eyes of a pediatric patient. When AML is present outside of the bone marrow and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results